If you’re in business development at a CDMO in Europe or North America, chances are CPhI Japan is the first event that comes to mind when exploring the Japanese pharmaceutical market. And on the surface, it makes sense: CPhI has global name recognition, and Japan is the world’s third-largest pharma market. But if you’re truly serious about entering Japan—especially as a contract development and manufacturing organization (CDMO)—there’s another event that deserves your attention far more: Interphex Japan.
This post aims to challenge the default assumption and explain why Interphex Japan might be the smarter, more strategic choice. Based on real-world insights and local experience, we’ll break down what makes Interphex Japan different, how it compares to CPhI Japan, and what you should know before deciding which show to attend.
The Common Misconception: “CPhI = Best for Japan”
Across the globe, CPhI has built a strong brand as the go-to pharma trade show for international networking. In Europe, CPhI is synonymous with global dealmaking, and its scale is unmatched. So it’s understandable that many international BD teams assume CPhI Japan will offer the same experience.
But that assumption misses the mark in Japan. Here, CPhI plays a very different role. While it’s still a respectable event, it tends to attract a more internationally oriented audience—foreign companies meeting other foreign companies, often with limited direct exposure to domestic Japanese pharma stakeholders.
In contrast, Interphex Japan is deeply integrated into Japan’s pharma ecosystem. It’s a must-attend event for domestic pharmaceutical companies, manufacturers, and technology providers—and that makes all the difference.
Interphex Japan vs. CPhI Japan: A Comparative Breakdown
According to discussions with the organizers of Interphex Japan, a significant development is on the horizon: until now, CMO and CDMO exhibitors have been grouped into a broader section within the exhibition. However, starting in 2026, a dedicated exhibition focused exclusively on CDMOs will be launched and co-located with Interphex. This strategic upgrade reflects the growing importance of the CDMO sector in Japan and highlights the organizers’ commitment to making the show more relevant and targeted for contract service providers.
Let’s take a closer look at how the two shows differ in terms of size, audience, and agenda:
| Criteria | Interphex Japan | CPhI Japan |
|---|---|---|
| Timing | July (Tokyo Big Sight) | April (Tokyo Big Sight) |
| Focus | Manufacturing, QA/QC, R&D, Pharma Tech | Ingredients, APIs, Licensing, BD |
| Typical Attendees | Domestic pharma companies, tech teams, QA reps | Overseas suppliers, trading companies |
| Visitor Volume | 31,977 attendees (2024) | 29,434 attendees (2024) |
Interphex Japan is where Japan’s pharma professionals go to learn about new manufacturing technologies, compliance solutions, and R&D tools. It’s where CDMOs can have serious conversations with real decision-makers—especially those responsible for selecting external partners.
Why Interphex Japan Is a Better Fit for CDMOs
For CDMOs, particularly those with advanced manufacturing or drug delivery technologies, Interphex offers several advantages over CPhI Japan:
1. Direct Access to Operational Decision-Makers
At Interphex, you’re far more likely to meet professionals from QA, QC, manufacturing, and formulation development—the exact people who evaluate external CDMO partners. These individuals rarely attend CPhI but make a point of showing up at Interphex.
2. Higher Concentration of Factory and Development Stakeholders
Interphex features a strong presence of equipment manufacturers—such as tableting machines and process technology—naturally attracting engineers, factory managers, and development personnel. This makes it an ideal venue to connect with those who influence outsourcing decisions at a technical level.
3. Stronger Reach Among Japanese Companies
In the minds of Japanese pharma professionals, Interphex—not CPhI—is the go-to exhibition. If your goal is to build connections with Japanese pharmaceutical companies and identify local business leads, Interphex offers greater visibility and credibility among domestic players.
Real-World Insights: From Someone Who’s Attended Both
Having attended both CPhI Japan and Interphex multiple times, I can tell you firsthand that the difference is stark.
From my personal experience—including my time working at Pfizer’s Nagoya plant—Interphex was consistently the event that colleagues and supervisors recommended for gaining exposure to Japan’s true pharmaceutical manufacturing landscape. Even back then, Interphex was seen as the industry-standard venue to learn about new technologies and meet relevant stakeholders.
In 2023 and 2024, I visited both Interphex and CPhI Japan. Interphex left a markedly stronger impression—particularly due to the high concentration of equipment manufacturers and real-life application booths. Scanning the visitor badges throughout the venue, I noticed many attendees from CDMOs and pharmaceutical manufacturers, mostly from operational departments such as production, engineering, and QC. This reinforced the idea that Interphex is not just a trade fair—it’s a functional arena for technical decision-makers.
At CPhI, by contrast, most conversations I overheard were between foreign companies and local agents. You’ll meet global players, but meaningful engagement with Japanese pharma companies tends to be shallow or limited to BD teams without operational authority.
At Interphex, I’ve seen mid-sized Japanese pharma companies send entire teams: heads of production, QC managers, and even executive-level decision-makers. They’re walking the floor to discover practical solutions, not just collect brochures.
In 2024, for example, a French CDMO client of ours exhibited at Interphex. They initially planned to only attend CPhI but changed course based on our advice. The result? Three technical discussions with domestic pharma companies, one of which led to a joint development feasibility study.
Interphex also fosters a collaborative atmosphere. Because the event includes not only pharma companies but also academia and regulatory experts, it creates an ecosystem conducive to serious, strategic discussions.
Recommendations for BD Teams Considering Their First Japan Event
If you’re exploring Japan for the first time, here’s what we recommend:
1. Attend Interphex Japan First
Use Interphex to get a real sense of the domestic landscape. Walk the floor, observe the booths, attend technical sessions (with interpretation help), and most importantly, talk to people. Even if you’re not ready to exhibit, attending can yield valuable insights.
2. Localize Your Presence
It will quickly become clear upon attending that local Japanese representation is not optional—it’s essential. Doing business in Japan requires more than just translation; it demands immersion in a uniquely structured pharmaceutical ecosystem. Japanese attendees will expect to interact with someone who understands local norms, regulations, and expectations. Consider how your strategy aligns with this reality, and invest in bilingual staff, local marketing materials, and experienced partners who can help bridge the cultural and operational gap.
3. Don’t Expect Immediate Deals
Building relationships in Japan takes time. Focus on credibility, transparency, and showing a long-term commitment to the market. A single visit won’t be enough, but Interphex is the right place to start the journey.
Final Thoughts: Interphex Japan Is Where Real Connections Happen
While trade shows are an important entry point, they are ultimately time-bound and limited in duration. If your goal is to establish real traction in Japan, then investing solely in a once-a-year event is not enough. What matters more is building a 365-day presence—one that demonstrates commitment, cultural fluency, and responsiveness to Japanese partners.
Establishing long-term visibility through local representation, Japanese-language media exposure, and consistent follow-up is what separates those who succeed in Japan from those who leave disappointed. Trade shows can open doors, but sustained presence builds trust.
Breaking into the Japanese pharmaceutical market is not easy. It requires time, cultural sensitivity, and strategic planning. Many overseas companies spend years attending the “wrong” shows and leave disappointed.
Interphex Japan, however, offers a gateway to real conversations, real decision-makers, and real opportunities. If you’re a CDMO ready to demonstrate your capabilities and start building trust in Japan, Interphex is where you need to be.
Let’s Talk: How WeBD.Tokyo Can Help
At WeBD.Tokyo, we specialize in helping overseas pharma and CDMO companies establish a presence in Japan. From joint booths at Interphex to bilingual business development and strategic introductions, our “Representation as a Service” model is designed for serious market entry.
Ready to explore Japan the right way?
Connect with us today, or subscribe to our newsletter for more practical insights on navigating Japan’s pharmaceutical landscape.
Keywords: Interphex Japan, pharma trade shows Japan, CPhI Japan vs Interphex